For example, an NLRP1 inflammasome inhibitor may be effective in patients with LN complicated by arthritis or erythema; an NLRP3 inflammasome inhibitor may be more effective in LN patients with NP-SLE. Here, NLRP3 is linked to systemic lupus erythematosus.